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Available online 26 July 2015AbstractDrug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an uncommon but potentially life-threatening cutaneous
hypersensitivity reaction characterized by extensive mucocutaneous eruption, fever, hematologic abnormalities including eosinophilia and/or
atypical lymphocytosis, and extensive organ involvement. Here, we describe a very rare case of DRESS syndrome in a female who had un-
dergone treatment with vancomycin for prosthetic valve endocarditis. According to the RegiSCAR scoring system, our case could be classified
as definite DRESS and cure was achieved with timely administration of methylprednisolone and antihistaminics.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Adverse drug reactions affecting skin are common and
present with a diverse pattern of expressions. Cutaneous hy-
persensitivity reactions range in severity, from mild reactions
to severe cutaneous adverse reactions (SCARs). SCARs are
rare in occurrence and include acute generalized exanthema-
tous pustulosis, drug reaction with eosinophilia and systemic
symptoms (DRESS), Stevens-Johnson syndrome, and toxic
epidermal necrolysis.1 To be included in SCAR, the following
criteria are to be fulfilled: (1) severe (associated to a signifi-
cant morbidity and mortality and usually leading to hospital-
ization); (2) nonpredictable (idiosyncratic, and probably of
immunological mechanism); and (3) most often induced by
drugs.1 DRESS is a distinct SCAR characterized by poten-
tially life-threatening hypersensitivity reaction with extensive
rash, fever, and internal organ involvement including liver and
kidney, occurring most commonly 2e6 weeks after initiation* Corresponding author. Department of Clinical and Experimental Pharma-
cology, Calcutta School of Tropical Medicine, 108, Chittaranjan Avenue,
Kolkata, West Bengal, 700073, India.
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2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. Publishedof a medication.2 Here, we describe a rare case of DRESS
syndrome caused by vancomycin.
2. Case Report
A 62-year-old female was admitted in a tertiary care hos-
pital with severe fever, progressive maculopapular skin rash,
eosinophilia along with hepatic and renal compromise. The
patient was alert and fully oriented. A diffuse, blanching er-
ythema was noted involving the face, trunk, and extremities
without desquamation (Figures 1 and 2). There was no
involvement of the oral mucosa, palms, or soles. The Nikolsky
test was negative. There were no lymph nodes enlargements.
Her medical history revealed that she had valvular heart
disease, for which prosthetic valve replacement was performed
~5 years back, and she was treated for prosthetic valve
endocarditis in a private clinic ~1 month back, where treat-
ment included vancomycin (2 g/d) due to infection by
methicillin-resistant Staphylococcus aureus. Vancomycin
serum concentration was checked to optimize therapy. The
trough level of vancomycin just before the fourth dose was
18 mg/dL. Since it was within the optimal range (15e20 mg/
dL), the dosage was continued without further adjustment.
There was no other concomitant medication at that time asby Elsevier Taiwan LLC. All rights reserved.
Figure 1. Skin rash in both hands in drug reaction with eosinophilia and
systemic symptoms (DRESS) syndrome with vancomycin.
Table 1
Investigational findings before starting vancomycin, after 3 weeks of vanco-
mycin, and after stoppage of vancomycin and 5 days of methylprednisolone
therapy.
Investigations Before starting
of vancomycin
At 3 wk of
vancomycin
After stoppage
of vancomycin
and 5 d of
methylprednisolone
Hemoglobin (g%) 10.5 10.5 10.5
Total leucocyte count
(n/mm3)
8000 15,000 12,000
Polymorphs (%) 55 53 53
Lymphocytes (%) 44 21 33
Eosinophils (%) 1 26 14
Absolute eosinophils
count (/mm3)
200 4100 1900
Atypical lymphocytes Absent Present Present
Platelets (/mm3) 2.2  105 2.2  105 2.2  105
Urea (mg/dL) 20 21 21
Creatinine (mg/dL) 1 3 2
Serum bilirubin (mg/dL) 0.8 3 1.3
Alanine aminotransferase
(ALT) (U/L)
24 148 94
Aspartate aminotransferase
(AST) (U/L)
28 356 220
Alkaline phosphatase (U/L) 60 185 84
Antinuclear antibody Negative Negative Negative
Urine protein Nil Traces Traces
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Approximately 3 weeks later, she started developing the
symptoms.
Important investigational findings of the patient before
starting vancomycin therapy and after 3 weeks of vancomycin
therapy, when the patient started developing the symptoms
(Table 1) revealed hematological, liver function and renal
function abnormalities. Tests for hepatitis A, hepatitis B,
hepatitis C, hepatitis E, human immunodeficiency virus 1, and
human immunodeficiency virus 2 were negative. Diagnosis
was confirmed using hematological results, liver functions
tests, renal profile, and excluding the other causes.
According to the RegiSCAR scoring system,3 our case
could be classified as having definite DRESS scoring 6 points,
as there was: fever þ, atypical lymphocytes þ, eosinophilia >
1500, skin rash 50%, with purpura and infiltration, and liver
and kidney involved. By Naranjo et al's4 scale, the causality
assessment of the syndrome with vancomycin revealed
‘probable’ with a score of 8. Cure was achieved with timely
administration of methylprednisolone and antihistaminics with
subsequently improved hematological, liver, and kidney
function parameters (Table 1).Figure 2. Skin rash in both legs in drug reaction with eosinophilia and systemic
symptoms (DRESS) syndrome with vancomycin.3. Discussion
Mild adverse cutaneous reactions to drugs are common,
occurring in up to 2e3% of all hospitalized patients.5 Of all
the cutaneous adverse reaction, 2% of cases are severe and
very few are fatal.6 DRESS syndrome is a potentially life-
threatening reaction along with involvement of multiple or-
gans. The syndrome has a latent onset, characteristically
occurring within 2e6 weeks after initial exposure to the
implicating drug. The earliest evidence of DRESS syndrome
can be traced to hydantoin drugs as early as the 1930s,
although a formal name for the syndrome was not coined until
the 1980s. The syndrome then became known by several
names, such as drug hypersensitivity syndrome, anticonvulsant
hypersensitivity syndrome, and phenytoin hypersensitivity
syndrome.2 The very name “drug rash with eosinophilia and
systemic symptoms” was first coined in 1996 by Bocquet et al2
to decrease the equivocality of the term “hypersensitivity
syndrome”. The estimated incidence of this syndrome ranges
from 1 in 1000 to 1 in 10,000 drug exposures.7 Recognizing
this syndrome and early management therein is of particular
importance, as the mortality rate of DRESS syndrome is up to
10%.8
Although most commonly associated with phenytoin, car-
bamazepine, and phenobarbital, DRESS syndrome has also
been reported after exposure to a myriad of medications
including lamotrigine, oxcarbazepine, sulfasalazine, doxycy-
cline, allopurinol, linezolid, nitrofurantoin, atorvastatin, eso-
meprazole, and vancomycin.8
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DRESS but it is a syndrome diagnosed by exclusion. The
main clinical features are rash, fever, hematological abnor-
malities, and organ involvement, all of which can be
nonspecific. The RegiSCAR scoring system has been
recently developed to delineate each of the SCARs as distinct
entities. RegiSCAR constitutes a European registry of
SCARs, including Stevens Johnson syndrome, toxic
epidermal necrolysis, acute generalized exanthematous pus-
tulosis, and DRESS. One of the aims of this registry is to
delineate each of these SCARs as distinct entities. To meet
the definition of DRESS, patients must have three of the four
main RegiSCAR criteria: an acute rash, fever > 38C,
lymphadenopathy at two sites, involvement of at least one
internal organ, and abnormalities in lymphocyte and eosin-
ophil counts. The scoring system grades suspected cases of
DRESS as “no”, “possible”, “probable” or “definite”.3
Whether there was any causal association between DRESS
and vancomycin, that has been determined using Naranjo
et al's4 algorithm, one of the widely accepted tools for cau-
sality assessment. Causality assessment is the evaluation of
the likelihood that a particular treatment is the cause of an
observed adverse event.9 The Naranjo et al's4 scale classifies
the probability that an adverse event is related to drug
therapy based on a list of weighted questions, which examine
factors such as the temporal association of drug adminis-
tration and event occurrence, alternative causes for the event,
drug levels, and previous patient experience with the medi-
cation, and thus categorize adverse drug reactions into defi-
nite, probable, possible, and doubtful accordingly.
The pathogenesis of DRESS syndrome is not yet well un-
derstood. Although it is considered an idiosyncratic reaction,
three potential causative factors have been identified among
multiple cases: (1) a defect in drug metabolism resulting in the
failure to eliminate toxic reactive intermediates; (2) reac-
tivation of human herpes virus 6, human herpes virus 7,
EpsteineBarr virus, or cytomegalovirus, which may serve as a
trigger for the reaction; and (3) a genetic predisposition that
alters immune response.8,10
Vancomycin, a glycopeptide antibiotic, is effective mostly
against Gram-positive bacteria. The Infectious Disease So-
ciety of America recommends vancomycin as a first-line
treatment for complicated skin infections, bloodstream in-
fections, endocarditis, bone and joint infections, and men-
ingitis infections caused by methicillin-resistant S. aureus.11
Vancomycin has been implicated in DRESS syndrome in
only a few studies previously.12,13 DRESS syndrome has
been reported since 1996 and the frequency of vancomycin-
associated DRESS syndrome has increased rapidly
recently.14 This may be due to more vigilance and thus, an
increased likelihood of diagnosis of this rare syndrome.
However, there is scarcity of published case reports of
DRESS with vancomycin in the literature from Indian
perspective. In this context, our case report will arouse
attention to the vancomycin-induced DRESS syndrome to
the medical fraternity.4. Conclusion
The diagnosis of DRESS is challenging. This variable
presentation, which may mimic many other diseases, can
make the diagnosis difficult, especially as this type of drug
reaction is more delayed than other drug reactions (i.e., usually
2e6 weeks instead of 1e3 weeks after the start of a certain
medication). However, prompt recognition of the syndrome
and withdrawal of the culprit drug is essential in this poten-
tially life-threatening, but mostly reversible reaction. Further
studies are required for early diagnosis of cases of DRESS, as
well as to formulate a better treatment protocol to diminish
morbidity and mortality arising from it.
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